I am only too optimistic if you think big pharma is going to stop undertaking trials for new compounds and therapies in AD. There are many different approaches under investigation and that is even before you get down to combination therapies such as Amyloid clearance with say Aricept or Alpha Cognition's Memogain (a galantamine prodrug) which stands a better than even chance of being approved in the next 12/18 months.
The prize is too big, the route to market is open or opening, not a chance in hell in my opinion that there will be anything other than a meaningful increase in AD trials overtime and that is before all of the other CNS areas that require digital measurement of cognition. I would also note that Medicare has very meaningfully increased its cost to members, they say in order to pay for AD treatments, so they obviously expect to be paying out in this area at some-point.
CGS Price at posting:
$1.68 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)